# CGTlive®

> CGTlive® - Healthcare Publication

- Base URL: https://www.cgtlive.com
- Generated: 2026-11-14T05:02:08.116Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.cgtlive.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.cgtlive.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.cgtlive.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.cgtlive.com/robots.txt](https://www.cgtlive.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Clinical Trials in Progress](https://www.cgtlive.com/clinical-trials-progress)
- [Conferences](https://www.cgtlive.com/conferences)
- [ImmunoLogic](https://www.cgtlive.com/immunologic)
- [News](https://www.cgtlive.com/news)
- [Rapid Readouts](https://www.cgtlive.com/rapid-readouts)
- [Sponsored](https://www.cgtlive.com/sponsored)
- [Topic](https://www.cgtlive.com/topic)
- [Videos](https://www.cgtlive.com/videos)

## Featured Content

- [Mivocabtagene Autoleucel Shows Durable 1-year Benefit in SPS, gMG](https://www.cgtlive.com/view/mivocabtagene-autoleucel-shows-durable-1-year-benefit-in-sps-gmg): One-year KYSA-8 and KYSA-6 data showed durable miv-cel benefit in SPS and gMG, supporting Kyverna's rolling BLA submission targeted for Q4 2026.
- [FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A](https://www.cgtlive.com/view/fda-approves-first-gene-therapy-for-sanfilippo-syndrome-type-a): FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, for pediatric patients with Sanfilippo syndrome type A, based on...
- [Ocugen Doses First Patient in Phase 3 Trial of OCU410 for GA](https://www.cgtlive.com/view/ocugen-doses-first-patient-phase-3-trial-ocu410-ga): Ocugen dosed the first patient in ArMaDa3, a global phase 3 trial of the one-time gene therapy OCU410 for geographic atrophy, following FDA RMAT desig...
- [Novartis, BMS Pause Autoimmune CAR-T Trials After Safety Events](https://www.cgtlive.com/view/novartis-bms-pause-autoimmune-car-t-trials-safety-events): Novartis suspended several autoimmune and neurology trials of rap-cel after 3 patient deaths linked to immune effector cell-associated hemophagocytic...
- [FDA Places New Clinical Hold On RGX-121 for Hunter Syndrome](https://www.cgtlive.com/view/fda-new-clinical-hold-rgx-121-hunter-syndrome): The FDA placed a new clinical hold on REGENXBIO's RGX-121 for Hunter syndrome after asymptomatic spine MRI findings were identified in 5 trial partici...
- [FDA Extends Deramiocel Review for Duchenne Muscular Dystrophy](https://www.cgtlive.com/view/fda-extends-deramiocel-review-dmd): The FDA extended its review of deramiocel for Duchenne muscular dystrophy to November 22, 2026, after accepting additional HOPE-3 data as a major BLA...
- [PTC Wins Sangamo's Fabry Gene Therapy in Bankruptcy Auction](https://www.cgtlive.com/view/ptc-wins-sangamo-fabry-gene-therapy-bankruptcy-auction): PTC Therapeutics wins Sangamo's BLA-stage Fabry disease gene therapy ST-920 for $111 million in a bankruptcy auction, with STAAR data supporting accel...
- [Pariglasgene Brecaparvovec-opnr Approved for Glycogen Storage Disease 1a](https://www.cgtlive.com/view/pariglasgene-brecaparvovec-opnr-approved-glycogen-storage-disease-1a): FDA granted accelerated approval to pariglasgene brecaparvovec-opnr, a one-time liver-directed AAV8 gene therapy, based on a 31% reduction in cornstar...
- [Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis](https://www.cgtlive.com/view/miv-cel-rmat-designation-progressive-multiple-sclerosis): FDA grants Kyverna's miv-cel RMAT designation in non-active secondary progressive MS, based on Phase 1 data showing CAR T expansion and B-cell reconst...
- [J&J Secures $2.58B Option to Acquire Sail Biomedicines](https://www.cgtlive.com/view/jj-secures-258-billion-option-to-acquire-sail-biomedicines): Johnson & Johnson secures an exclusive option to acquire Sail Biomedicines for $2.58 billion, backing the biotech's in vivo CAR T platform for immune-...

## Feeds and Indexes

- [RSS Feed](https://www.cgtlive.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.cgtlive.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.cgtlive.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.cgtlive.com/authors): Browse all contributors and their published work